FDA approved AstraZeneca’s Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
FDA approved AstraZeneca’s Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
Copyright © Louis Velazquez. All Rights Reserved.